Effect of APOE ε4 Genotype on Metabolic Biomarkers in Aging and Alzheimer’s Disease.

Jill Morris K, Roxanne Adeline Z Uy, Eric D Vidoni, Heather M Wilkins, Ashley E Archer, John P Thyfault, John M Miles, Jeffrey M Burns,


Journal of Alzheimer's disease : JAD, May 27, 2017


Alzheimer’s disease (AD) may have heterogeneous pathophysiological underpinnings, with risk factors including apolipoprotein rmvarep4 (APOE4) genotype and insulin resistance. We hypothesized that distinct phenotypes exist within AD. We examined APOE4 and metabolic biomarkers in 338 subjects (n = 213 nondemented (ND), n = 125 AD). We further characterized steady state free fatty acid (FFA) levels in a subset of 45 participants who had also participated in a hyperinsulinemic-euglycemic clamp. Insulin resistance (HOMA-IR) was elevated in AD versus ND (p = 0.04) and in APOE4 noncarriers versus carriers (p 


Pubmed Link: 28550261

DOI: 10.3233/JAD-170148